Person: OKUYAN, BETÜL
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
OKUYAN
First Name
BETÜL
Name
10 results
Search Results
Now showing 1 - 10 of 10
Publication Metadata only Preparing future pharmacists to provide effective behaviour change support in pharmaceutical care consultations: early adoption of the Train4Health educational products(2022-06-01) OKUYAN, BETÜL; OKUYAN B., Henriques H. R., Felix I. B., Braam K., Pimenta N., Guerreiro M. P., Carmo M. B.Publication Metadata only Assessment of medication literacy in breastfeeding women: preliminary data(2022-12-01) SANCAR, MESUT; OKUYAN, BETÜL; Ucar N., SANCAR M., Sezerol M. A., Buyukkayh D., Tasci Y., OKUYAN B.Publication Metadata only Medication adherence barriers in Turkish patients with chronic diseases(2022-12-01) SANCAR, MESUT; AY, NADİYE PINAR; OKUYAN, BETÜL; Yagmur M., SANCAR M., Ay P., Abdi A., Samuelyan N., OKUYAN B.Publication Metadata only Development of a theory planned behavior based scale to assess turkish clinical pharmacists' intention to provide pharmaceutical care(2022-12-01) SANCAR, MESUT; OKUYAN, BETÜL; ÖZDEMİR N., Tecen-Yucel K., KARA E., Demirkan K., SANCAR M., OKUYAN B.Publication Metadata only Factors associated with intention of breastfeeding and pregnant women to have the Coronavirus vaccine(2022-12-01) OKUYAN, BETÜL; Ucar N., Bayrak O., Buyukkayh D., Cetin A., OKUYAN B.Publication Metadata only Therapeutic drug monitoring in pediatric patients treated with anti-tuberculosis medications by high performance liquid chromatography(2022-01-01) OKUYAN, BETÜL; TOK, FATİH; KARAKUŞ, SEVGİ; KAYMAKÇIOĞLU, BEDİA; SANCAR, MESUT; OKUYAN B., TOK F., KARAKUŞ S., Dalgiç N., ÇAKIR E., Midyat L., Koçyiğit-Kaymakçioğlu B., Berk U. E. , İZZETTİN F. V. , Rollas S., et al.© 2022 Marmara University Press.The aim of this study is to perform therapeutic drug monitoring for isoniazid (INH), rifampicin (RIF), and pyrazinamide (PZA) in pediatric tuberculosis patients. The study was carried out in 3 different training-research hospitals in Istanbul, Türkiye between 2011 and 2012. The pediatric patients (aged ≤14 years) who initiated the standard primary anti-tuberculosis therapy were included in this study. The serum samples were collected 3 hours after the first medication doses were given on the 5th day of treatment. Chromatographic experiments were performed on an Agilent 1100 High-Performance Liquid Chromatography (HPLC) system, and the separation was carried out on a Nova-Pak C18 (3.9x150 mm, 5 μm, Merck) analytical column. In this HPLC method, the gradient elusion delivered 3% to 40% (v/v) acetonitrile in phosphate buffer was used, and diode array detector. Twenty-three children (60.9% male) patients were included with a mean age of 111.70 ± 59.94 months. Plasma levels were measured sub-therapeutically for INH in 14, RIF in 10, and PZA in 5 patients, according to the normal range of adult patients. Maximum plasma concentrations after three hours were found between 0.53-14.02 mg/L for INH, 11.17-60.39 mg/L for PZA, 2.15-16.75 mg/L for RIF. In conclusion, this method has been successfully applied to simultaneously determine RIF, INH, and PZA plasma levels in pediatric tuberculosis patients. RIF and INH plasma levels were found to be lower in pediatric patients with tuberculosis compared to target range of adult patients.Publication Metadata only Clinical Pharmacist-Led Medication Review in Hospitalized Confirmed or Probable Patients with COVID-19 During the First Wave of COVID-19 Pandemic(2024-01-01) ÜNDER, DUYGU; ENVER, CÜNEYD; DEMİRCİ, MUHAMMED YASİR; AYHAN, YUNUS EMRE; ÖZGAN, BETÜL; İLERLER, ENES EMİR; OKUYAN, BETÜL; ERTÜRK ŞENGEL, BUKET; KOCAKAYA, DERYA; SİLİ, ULUHAN; TİGEN, ELİF; KARAKURT, SAİT; KORTEN, VOLKAN; SANCAR, MESUT; ÜNDER D., ENVER C., DEMİRCİ M. Y., AYHAN Y. E., ÖZGAN B., İLERLER E. E., OKUYAN B., ERTÜRK ŞENGEL B., KOCAKAYA D., SİLİ U., et al.Objectives: Drug-related problems (DRPs) result in serious problems among hospitalized patients, high rates of morbidity and mortality, and increased healthcare costs. This study aimed to identify DRPs by clinical pharmacist-led medication review in hospitalized probable patients with coronavirus disease-2019 (COVID-19) during the first wave of the COVID-19 pandemic. Materials and Methods: This retrospective cross-sectional study was conducted at the COVID-19 inpatient services of a tertiary university hospital in Türkiye for 3 months (between March 2020 and June 2020) and included hospitalized confirmed or probable COVID-19 patients. The World Health Organization and Turkish Ministry of Health Guidelines case definitions were used to define confirmed and probable COVID-19 patients. Six clinical pharmacy residents provided medication review services during their education and training. DRPs were classified based on the Pharmaceutical Care Network Europe V9.00. The physician’s acceptance rate of clinical pharmacists’ recommendations was assessed. Results: Among 202 hospitalized patients with probable or confirmed COVID-19, 132 (65.3%) had at least one drug-related problem. Two hundred and sixty-four DRPs were identified. Drug selection (85.6%) and dose selection (9.2%) were the most common causes of these problems. Among the 80 clinical pharmacist interventions, 48.8% were accepted by the physicians. Conclusion: Clinical pharmacists identified a significant number of DRPs during the COVID-19 pandemic, particularly those related to drug interactions and drug safety, such as adverse drug reactions. This study highlights the importance of detecting and responding to DRPs in the COVID-19 pandemic.Publication Metadata only Development of virtual education module to promote Turkish community pharmacist-led pharmaceutical care services in older patients(2022-12-01) OKUYAN, BETÜL; SANCAR, MESUT; OKUYAN B., Ozcan V., Balta E., Albayrak O. D., Turker M., SANCAR M., Yavuz B. B., ÜNER S., ÖZCEBE L. H.Publication Metadata only Prescribing patterns of potentially inappropriate medication use in older patients in Europe: the results from the EUROAGEISM H2020 project(2022-12-01) ALTIPARMAK, ÖZNUR; OKUYAN, BETÜL; Brkic J., Drzaic M., Kummer I., Hadziabdic M. O., Sesto S., Tadic I., Altiparmak O., OKUYAN B., Bobrova V., Volmer D., et al.Publication Metadata only Intentional medication adherence problems in Turkish older patients(2022-12-01) OKUYAN, BETÜL; SANCAR, MESUT; OKUYAN B., Ozcan V., Balta E., Albayrak O. D., Turker M., SANCAR M., Yavuz B. B., ÜNER S., ÖZCEBE L. H.